[Adhesion prevention after Cesarean section by short-term biological barrier of modified chitosan].
OBJECTIVE
To evaluate the efficacies of modified chitosan, an adhesive prevention substance, as a biological barrier for preventing adhesion after Cesarean section.


METHODS
A total of 250 cases undergoing primary Cesarean section from January 2011 to June 2012 at our hospital were recruited. They were randomly divided into experiment (n = 130) and control (n = 120) groups. The experiment group received modified chitosan during Cesarean section while no adhesive prevention substance was offered for the control group. Postoperative flatus time, postoperative infection and pelvic adhesion were used to evaluate the clinical efficacies.


RESULTS
For the experiment group, the average postoperative flatus time was (25 ± 7) hours. Three cases had postoperative infections with a postoperative infection rate of 2.3%. There were 2 cases of pelvic adhesion (pelvic adhesion rate: 1.5%) during the postoperative follow-up period. For the control group, the average postoperative flatus time was (34 ± 11) hours. Five cases had postoperative infections with a postoperative infection rate of 4.2%. There were 5 cases of pelvic adhesion (pelvic adhesion rate: 4.2%) during the postoperative follow-up period. There were significant inter-group differences in postoperative flatus time, postoperative infection and pelvic adhesion (P < 0.05).


CONCLUSIONS
Modified chitosan can prevent pelvic adhesion after Cesarean section.
Department of Obstetrics & Gynecology, Zhejiang Xiaoshan Hospital, Hangzhou 311202, China; Jiaxing Strong Biological Technology Co., Ltd, Jiaxing 314000, China. Email: shen@zjxsh.com.
Wei
W
Shen
Department of Obstetrics & Gynecology, Zhejiang Xiaoshan Hospital, Hangzhou 311202, China; Jiaxing Strong Biological Technology Co., Ltd, Jiaxing 314000, China.
Guofang
G
Shen
Department of Obstetrics & Gynecology, Zhejiang Xiaoshan Hospital, Hangzhou 311202, China; Jiaxing Strong Biological Technology Co., Ltd, Jiaxing 314000, China.
Lüwei
L
Li
D002585:Cesarean Section / Q000009:adverse effects* / Q000379:methods; D048271:Chitosan / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control*; D011247:Pregnancy; D000267:Tissue Adhesions / Q000517:prevention & control*
D048271:Chitosan